Real‐World Effectiveness of All‐Oral Direct‐Acting Antivirals in Patients With Hepatitis C Virus‐Related HCC
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3481 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Shao-Hsuan Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Antiviral Agents, Liver Neoplasms, Hepatitis C, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.
Abstract (Originalsprache)
The association between direct‐acting antiviral (DAA) treatment and hepatitis C virus (HCV)‐related hepatocellular carcinoma (HCC) is currently unclear. Hence, we aim to assess the association between DAA treatment and mortality rate among Medicare beneficiaries with HCV‐related HCC. This retrospective cohort study screened 19,813 adults in 2013–2019 Surveillance, Epidemiology, and End Results data linked with Medicare data. Patients with HCV‐related HCC initiating DAA therapy after their first HCC diagnosis were compared with patients with HCV‐related HCC who received no HCV treatment. After inverse probability treatment weighting, multivariable Cox proportional hazards models compared mortality rates between the groups. Subgroup and sensitivity analyses were based on HCC stage (early vs. advanced), type of HCC treatment (curative, palliative, none), and DAA treatment duration. In total 3,777 patients with HCV‐related HCC were identified (mean age: 68.2 years, 75.2% male, 61.8% White), of whom 19% initiated DAA therapy. Crude incidence mortality rates were 17.9 and 90.7 deaths per 100 person‐years in the DAA and HCV‐untreated groups, respectively. Cox regression models indicated that DAA therapy was associated with decreased risk of all‐cause mortality (adjusted hazard ratio, 0.33; 95% CI 0.31–0.36). Median survival time was 45.7 (95% CI 40.9–57.9) months in the DAA group and 7.7 (95% CI 7.3–8.2) months in the HCV‐untreated group ( P < 0.001). All subgroup and sensitivity analyses were consistent with the main analyses. DAA therapy was associated with survival benefits for patients with HCV‐related HCC regardless of the stage or type of HCC treatment and should not be withheld from this population of Medicare beneficiaries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, University of Florida, Gainesville, Florida, USA.
- Health Outcomes Division, College of Pharmacy, University of Texas at Austin, Austin, Texas, USA.
ORCID-Profile: Shao-Hsuan Chang, Chanhyun Park, Jingchuan Guo, Haesuk Park
Förderung
- NIDA NIH HHS
Zitieren
APA
Chang, S. H., Cabrera, R., Heo, J., Park, C., Guo, J., & Park, H. (2025). Real‐World Effectiveness of All‐Oral Direct‐Acting Antivirals in Patients With Hepatitis C Virus‐Related HCC. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3481
Vancouver
Chang SH, Cabrera R, Heo J, Park C, Guo J, Park H. Real‐World Effectiveness of All‐Oral Direct‐Acting Antivirals in Patients With Hepatitis C Virus‐Related HCC. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3481
BibTeX
@article{Chang2025,
author = {Chang, Shao-Hsuan and Cabrera, Roniel and Heo, Jihaeng and Park, Chanhyun and Guo, Jingchuan and Park, Haesuk},
title = {Real‐World Effectiveness of All‐Oral Direct‐Acting Antivirals in Patients With Hepatitis C Virus‐Related HCC},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3481}
}
EUVIMED